0001181431-13-054616.txt : 20131021
0001181431-13-054616.hdr.sgml : 20131021
20131021163114
ACCESSION NUMBER: 0001181431-13-054616
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131018
FILED AS OF DATE: 20131021
DATE AS OF CHANGE: 20131021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC.
CENTRAL INDEX KEY: 0001401667
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770683487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: (424) 248-6500
MAIL ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP
DATE OF NAME CHANGE: 20070601
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WILSON TROY EDWARD
CENTRAL INDEX KEY: 0001589597
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35703
FILM NUMBER: 131161684
MAIL ADDRESS:
STREET 1: C/O PUMA BIOTECHNOLOGY INC.
STREET 2: 10880 WILSHIRE BOULEVARD, SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
4
1
rrd393046.xml
WILSON F4
X0306
4
2013-10-18
0
0001401667
PUMA BIOTECHNOLOGY, INC.
PBYI
0001589597
WILSON TROY EDWARD
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES
CA
90024
1
0
0
0
STOCK OPTION (RIGHT TO BUY)
44.96
2013-10-18
4
A
0
40000
0
A
2023-10-18
COMMON STOCK
40000
40000
D
The vesting commencement date ("Vesting Commencement Date") of the option is October 18, 2013. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to one-thirty sixth (1/36th) of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to (a) the Reporting Person's continued service on the Audit Committee, with respect to 10,000 of the 40,000 underlying shares, and (b) the Reporting Person's continued service with the Issuer, with respect to the remaining 30,000 of the 40,000 underlying shares.
/s/ Troy Edward Wilson
2013-10-21